Evidence map›Paper›PMID 34452073›Full record

ArticlePharmaceutics2021

Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance.

Ayça Altay Benetti, Annalisa Bianchera, Francesca Buttini, Laura Bertocchi, Ruggero Bettini

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Dry powder formulations of hyperimmune serum.Drug delivery and translational research · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ayça Altay BenettiDepartment of Food and Drug Sciences, University of Parma, Parco Area delle Scienze, Building 8, 43124 Parma, Italy.ORCID 0000-0001-8072-1606
Annalisa BiancheraDepartment of Food and Drug Sciences, University of Parma, Parco Area delle Scienze, Building 8, 43124 Parma, Italy.ORCID 0000-0002-3160-9586
Francesca ButtiniDepartment of Food and Drug Sciences, University of Parma, Parco Area delle Scienze, Building 8, 43124 Parma, Italy.ORCID 0000-0002-4472-4823
Laura BertocchiDepartment of Food and Drug Sciences, University of Parma, Parco Area delle Scienze, Building 8, 43124 Parma, Italy.
Ruggero BettiniDepartment of Food and Drug Sciences, University of Parma, Parco Area delle Scienze, Building 8, 43124 Parma, Italy.ORCID 0000-0002-3857-7476
University of Parma · IT

Funding

Regione Emilia-Romagna PG/2015/731196
6 · The paper itself

Abstract

The search for best performing carriers for dry powder inhalers is getting a great deal of interest to overcome the limitations posed by lactose. The aerosolization of adhesive mixtures between a carrier and a micronized drug is strongly influenced by the carrier solid-state properties. This work aimed at crystallizing kinetically stable D-mannitol polymorphs and at investigating their aerosolization performance when used in adhesive mixtures with two model drugs (salbutamol sulphate, SS, and budesonide, BUD) using a median and median/high resistance inhaler. A further goal was to assess in vitro the cytocompatibility of the produced polymer-doped mannitol polymorphs toward two lung epithelial cell lines. Kinetically stable (up to 12 months under accelerate conditions) α, and δ mannitol forms were crystallized in the presence of 2%

Indexed as

aerosolizationbudesonideDPI carrierinhaler resistancein vitro toxicitymannitol polymorphssalbutamol sulphate

Identifiers

PMID34452073
PMCPMC8401007
OpenAlexW3185810740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.